top of page
MYELOMA CLINICAL TRIALS - PHASE 1/2


Dec 2, 2022
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
MagnetisMM-8 NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory...
281


Dec 1, 2022
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...
169


Dec 1, 2022
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812: Phase 1/2 Study of ISB 1442 in...
153


Dec 1, 2022
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480...
422


Dec 1, 2022
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma This is a two-stage...
315


Dec 16, 2021
NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
FUMANBA-1 NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory...
140


Dec 16, 2021
NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML
NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML NCT04887259: Phase 1/2: Trial of LAVA-051...
59


Dec 11, 2021
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an...
255


Dec 8, 2021
NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma
NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma Descartes-25 in Relapsed/Refractory Multiple Myeloma This is...
222


Dec 7, 2021
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
BelaRd Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (BelaRd) NCT04808037:...
302


Dec 1, 2021
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05060627: An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed...
146


Dec 1, 2021
NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of...
238


Dec 1, 2021
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...
998


Aug 19, 2021
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...
365


Aug 11, 2021
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With...
149


Aug 6, 2021
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in...
59


Jun 27, 2021
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma...
196


Jun 22, 2021
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients Study of FasT CAR-T GC012F Injection in High...
345


Jun 17, 2021
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...
227


Jun 10, 2021
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies GEN3014 Safety Trial in Relapsed or...
159


Jun 5, 2021
NCT04756726: Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...
472


Jun 2, 2021
NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma Relapsed & Refractory Myeloma NCT04822337:...
110


Jun 2, 2021
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06 NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma...
205


Dec 29, 2020
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...
856


Dec 23, 2020
NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma
NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple...
56


Dec 19, 2020
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple...
68


Dec 18, 2020
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma...
84


Dec 12, 2020
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38...
219


Dec 1, 2020
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple...
143


Dec 1, 2020
NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma - RRMM - CARAMBA-1
CARAMBA-1 - NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma CARAMBA-1 - NCT04499339: Phase 1/2: Autologous...
36


Dec 1, 2020
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
BelaCarD Study AMaRC: (PHASE I/II) BELACARD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA A phase I/II single arm study on the efficacy of...
154


Dec 20, 2019
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors A Phase...
102


Dec 13, 2019
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM
Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459 NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With...
241


Dec 12, 2019
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in...
34


Dec 12, 2019
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3...
247


Dec 11, 2019
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...
756


Dec 10, 2019
NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM The purpose of this study is to infuse BCMA CAR-NK 92 cells to...
371


Dec 7, 2019
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217...
214


Dec 5, 2019
NCT04126200: Phase 1/2 - Belantamab Mafodotin as Monotherapy & With Anti-cancer Rx (RRMM) (DREAMM 5)
DREAMM 5 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With...
372


Dec 4, 2019
NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM
NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM Ixazomib + Pomalidomide + Dexamethasone In MM This is a Phase I/II...
74


Dec 1, 2019
NCT03848845: Phase 1/2: GSK2857916 in Combination With Pembrolizumab in RRMM Myeloma- DREAMM 4
NCT03848845: Phase 1/2: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in...
56


Dec 31, 2018
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...
810


Dec 30, 2018
NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab
NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab The purpose of this study is to test...
237


Dec 26, 2018
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...
689


Dec 20, 2018
NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)
EVOLVE Autologous BCMA-specific CAR-T cells JCARH125 NCT03430011: Phase 1/2 - Study Evaluating the Safety and Efficacy of JCARH125 in...
140


Dec 12, 2018
NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM
Multiple Myeloma Research Consortium NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for...
142


Dec 9, 2018
NCT03715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex - Algonquin trial
Algonquin trial, a multi-center Canadian phase I, two-part, dose-escalation study This is a Phase 1/2, multi-centre, single-arm,...
586


Dec 7, 2018
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma This Phase I study will test the safety and anti-myeloma...
258
bottom of page